Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

Naveed Sattar(British Heart Foundation), David Preiss(University of Glasgow), Heather Murray(University of Glasgow), Paul Welsh(University of Glasgow), Brendan M. Buckley(Cork University Hospital), Anton JM de Craen(Leiden University), Sreenivasa Rao Kondapally Seshasai(University of Cambridge), John J.V. McMurray(University of Glasgow), Dilys J. Freeman(University of Glasgow), J. Wouter Jukema(Leiden University), Peter W. Macfarlane(University of Glasgow), Chris J. Packard(University of Glasgow), David J. Stott(University of Glasgow), Rudi G. J. Westendorp(Netherlands Consortium for Healthy Ageing), James Shepherd(University of Glasgow), Barry R. Davis, Sara Pressel, Roberto Marchioli(Mario Negri Sud Foundation), Rosa Maria Marfisi(Mario Negri Sud Foundation), Aldo P. Maggioni(Associazione Nazionale Medici Cardiologi Ospedalieri), Luigi Tavazzi(CARE Hospitals), Gianni Tognoni(Mario Negri Sud Foundation), John Kjekshus(Oslo University Hospital), Terje R. Pedersen(Oslo University Hospital), Thomas J. Cook(Agile RF (United States)), Antonio M. Gotto(Cornell University), Michael Clearfield(Moscow University Touro), John R. Downs(The University of Texas at San Antonio Health Science Center), Haruo Nakamura(Mitsukoshi Health and Welfare Foundation), Yasuo Ohashi(The University of Tokyo), Kyoichi Mizuno(Nippon Medical School), Kausik K. Ray(University of Cambridge), Ian Ford(University of Glasgow)
The Lancet
February 1, 2010
10.1016/s0140-6736(09)61965-6
Cited by 2,441

Abstract

Related Papers

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
Peter Sever, Björn Dahlöf, Neil R Poulter et al.|The Lancet|2003|3.8k
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial
Rory Collins, Jane Armitage, Sarah Parish et al.|The Lancet|2003|2.9k
High-Dose Atorvastatin after Stroke or Transient Ischemic Attack
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators|New England Journal of Medicine|2006|2.9k
Replication of Genome-Wide Association Signals in UK Samples Reveals Risk Loci for Type 2 Diabetes
Eleftheria Zeggini, Michael N. Weedon, Cecilia M. Lindgren et al.|Science|2007|2.2k
Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis
Cholesterol Treatment Trialists' (CTT) Collaborators|The Lancet|2008|2.1k